... These drugs, which are typically used in people who can’t tolerate chemotherapy or are older, include: Enasidenib (Idhifa) Midostaurin (Rydapt) Venetoclax (Venclexta) Ivosidenib (Tibsovo) Gilteritinib (Xospata) Treatments for CML Blast CrisisThe BCR-ABL gene encodes a protein known as a tyrosine kinase. ...
How Is AML Different From CML Blast Crisis?
... These drugs, which are typically used in people who can’t tolerate chemotherapy or are older, include: Enasidenib (Idhifa) Midostaurin (Rydapt) Venetoclax (Venclexta) Ivosidenib (Tibsovo) Gilteritinib (Xospata) Treatments for CML Blast CrisisThe BCR-ABL gene encodes a protein known as a tyrosine kinase. ...
... Ivosidenib (Tibsovo) can help treat people with IDH1 mutations, while enasidenib (Idhifa) is a treatment option for people with IDH2 mutations. Certain people with AML may also be able to take glasdegib (Daurismo). ...
The Benefits of Targeted Therapy for Leukemia
... Ivosidenib (Tibsovo) can help treat people with IDH1 mutations, while enasidenib (Idhifa) is a treatment option for people with IDH2 mutations. Certain people with AML may also be able to take glasdegib (Daurismo). ...
... People with a mutation in the IDH1 gene can use ivosidenib (Tibsovo) or olutasidenib (Rezlidhia). People with a mutation in the IDH2 gene can use enasidenib (Idhifa). ...
... People with relapsed or refractory AML with an IDH1 gene mutation can be treated with Tibsovo (ivosidenib). People with AML and a mutation in the FLT3 gene may be able to use Xospata (Gilteritinib) or Rydapt (midostaurin). ...
... IDH inhibitors include: Enasidenib (Idhifa) Ivosidenib (Tibsovo) Menin InhibitorsMenin inhibitors, like revumenib (Revuforj), are a newer class of targeted therapies specifically designed for cases of acute leukemia with a lysine methyltransferase 2A (KMT2A) gene translocation. ...
8 Leukemia Treatment Options You Should Know
... IDH inhibitors include: Enasidenib (Idhifa) Ivosidenib (Tibsovo) Menin InhibitorsMenin inhibitors, like revumenib (Revuforj), are a newer class of targeted therapies specifically designed for cases of acute leukemia with a lysine methyltransferase 2A (KMT2A) gene translocation. ...